Abstract
Seven patients with myeloblastic leukemia were treated for 10 days with high-dose (15 or 30 million units/m2/day), human lymphoblastoid interferon (Wellferon) by continuous iv infusion. All patients developed prolonged activated partial thromboplastin time, and four developed prolonged prothrombin time. Factor assays demonstrated low levels of II, VII, IX, X, and XII. Coagulation abnormalities improved after discontinuation of interferon therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Blood Coagulation Disorders / blood
-
Blood Coagulation Disorders / etiology*
-
Blood Coagulation Factors / analysis
-
Blood Coagulation Tests
-
Child
-
Child, Preschool
-
Drug Evaluation
-
Humans
-
Infant
-
Interferon Type I / administration & dosage
-
Interferon Type I / adverse effects*
-
Interferon Type I / therapeutic use
-
Leukemia, Myeloid, Acute / therapy
-
Retrospective Studies
Substances
-
Blood Coagulation Factors
-
Interferon Type I